• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mink Therapeutics Inc (NQ: INKT )

    0.7090 -0.0050 (-0.70%)
    Streaming Delayed Price Updated: 3:52 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Mink Therapeutics Inc

    < Previous 1 2 3 4 Next >
    MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
    From MiNK Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Earnings Outlook For MiNK Therapeutics
    Via Benzinga
    MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
    From MiNK Therapeutics
    Via GlobeNewswire
    INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024
    INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    MiNK Reports Second Quarter 2024 Results and Business Update
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
    From MiNK Therapeutics
    Via GlobeNewswire
    INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024
    INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    MiNK Reports First Quarter 2024 Results
    From MiNK Therapeutics
    Via GlobeNewswire
    Why MiNK Therapeutics Stock Is Up 11% Monday
    MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
    From MiNK Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
    From MiNK Therapeutics
    Via GlobeNewswire
    Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023
    INKT stock results show that MiNK Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    MiNK Reports Fourth Quarter and Year-End 2023 Results
    From MiNK Therapeutics
    Via GlobeNewswire
    MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
    From MiNK Therapeutics
    Via GlobeNewswire
    Earnings Scheduled For March 21, 2024
    Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
    Via Benzinga
    MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
    MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model 
    From MiNK Therapeutics
    Via GlobeNewswire
    First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
    From MiNK Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.